Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.26
DEPO's Cash to Debt is ranked lower than
84% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. DEPO: 0.26 )
Ranked among companies with meaningful Cash to Debt only.
DEPO' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: 0.26

Equity to Asset 0.51
DEPO's Equity to Asset is ranked lower than
67% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. DEPO: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
DEPO' s 10-Year Equity to Asset Range
Min: -2.63   Max: 0.97
Current: 0.51

-2.63
0.97
Interest Coverage 9.90
DEPO's Interest Coverage is ranked lower than
79% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2145.51 vs. DEPO: 9.90 )
Ranked among companies with meaningful Interest Coverage only.
DEPO' s 10-Year Interest Coverage Range
Min: 1.73   Max: 9999.99
Current: 9.9

1.73
9999.99
F-Score: 5
Z-Score: 4.57
M-Score: -1.51
WACC vs ROIC
22.40%
140.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 55.26
DEPO's Operating margin (%) is ranked higher than
98% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.81 vs. DEPO: 55.26 )
Ranked among companies with meaningful Operating margin (%) only.
DEPO' s 10-Year Operating margin (%) Range
Min: -12972.91   Max: 72.49
Current: 55.26

-12972.91
72.49
Net-margin (%) 29.53
DEPO's Net-margin (%) is ranked higher than
94% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.82 vs. DEPO: 29.53 )
Ranked among companies with meaningful Net-margin (%) only.
DEPO' s 10-Year Net-margin (%) Range
Min: -14964.35   Max: 75.05
Current: 29.53

-14964.35
75.05
ROE (%) 38.49
DEPO's ROE (%) is ranked higher than
93% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. DEPO: 38.49 )
Ranked among companies with meaningful ROE (%) only.
DEPO' s 10-Year ROE (%) Range
Min: -1132.2   Max: 539.95
Current: 38.49

-1132.2
539.95
ROA (%) 16.56
DEPO's ROA (%) is ranked higher than
89% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. DEPO: 16.56 )
Ranked among companies with meaningful ROA (%) only.
DEPO' s 10-Year ROA (%) Range
Min: -201.37   Max: 73.87
Current: 16.56

-201.37
73.87
ROC (Joel Greenblatt) (%) 180.81
DEPO's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.39 vs. DEPO: 180.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DEPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2396.53   Max: 7997.51
Current: 180.81

-2396.53
7997.51
Revenue Growth (3Y)(%) 35.50
DEPO's Revenue Growth (3Y)(%) is ranked higher than
93% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. DEPO: 35.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DEPO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -69.7   Max: 420.5
Current: 35.5

-69.7
420.5
EBITDA Growth (3Y)(%) 43.20
DEPO's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. DEPO: 43.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DEPO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -55.8   Max: 84.2
Current: 43.2

-55.8
84.2
EPS Growth (3Y)(%) 16.50
DEPO's EPS Growth (3Y)(%) is ranked higher than
70% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. DEPO: 16.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DEPO' s 10-Year EPS Growth (3Y)(%) Range
Min: -59.5   Max: 180.9
Current: 16.5

-59.5
180.9
» DEPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

DEPO Guru Trades in Q2 2014

Joel Greenblatt 937,085 sh (New)
George Soros 75,600 sh (New)
Paul Tudor Jones 40,112 sh (-36.96%)
» More
Q3 2014

DEPO Guru Trades in Q3 2014

Steven Cohen 448,900 sh (New)
Joel Greenblatt 1,637,713 sh (+74.77%)
Paul Tudor Jones 64,690 sh (+61.27%)
George Soros Sold Out
» More
Q4 2014

DEPO Guru Trades in Q4 2014

Joel Greenblatt 1,218,263 sh (-25.61%)
Paul Tudor Jones 42,365 sh (-34.51%)
Steven Cohen 151,800 sh (-66.18%)
» More
Q1 2015

DEPO Guru Trades in Q1 2015

Joel Greenblatt 1,414,563 sh (+16.11%)
Paul Tudor Jones 42,414 sh (+0.12%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.40
DEPO's P/E(ttm) is ranked higher than
80% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.90 vs. DEPO: 16.40 )
Ranked among companies with meaningful P/E(ttm) only.
DEPO' s 10-Year P/E(ttm) Range
Min: 2.36   Max: 121.85
Current: 16.4

2.36
121.85
Forward P/E 16.21
DEPO's Forward P/E is ranked higher than
71% of the 427 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.72 vs. DEPO: 16.21 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 15.80
DEPO's PE(NRI) is ranked higher than
81% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.70 vs. DEPO: 15.80 )
Ranked among companies with meaningful PE(NRI) only.
DEPO' s 10-Year PE(NRI) Range
Min: 2.36   Max: 123.38
Current: 15.8

2.36
123.38
P/B 3.50
DEPO's P/B is ranked higher than
53% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. DEPO: 3.50 )
Ranked among companies with meaningful P/B only.
DEPO' s 10-Year P/B Range
Min: 2   Max: 48.18
Current: 3.5

2
48.18
P/S 4.13
DEPO's P/S is ranked lower than
61% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.04 vs. DEPO: 4.13 )
Ranked among companies with meaningful P/S only.
DEPO' s 10-Year P/S Range
Min: 1.38   Max: 752
Current: 4.13

1.38
752
PFCF 240.00
DEPO's PFCF is ranked lower than
91% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.02 vs. DEPO: 240.00 )
Ranked among companies with meaningful PFCF only.
DEPO' s 10-Year PFCF Range
Min: 2.37   Max: 307.17
Current: 240

2.37
307.17
POCF 207.60
DEPO's POCF is ranked lower than
95% of the 444 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.61 vs. DEPO: 207.60 )
Ranked among companies with meaningful POCF only.
DEPO' s 10-Year POCF Range
Min: 2.29   Max: 276.45
Current: 207.6

2.29
276.45
EV-to-EBIT 7.41
DEPO's EV-to-EBIT is ranked higher than
95% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.90 vs. DEPO: 7.41 )
Ranked among companies with meaningful EV-to-EBIT only.
DEPO' s 10-Year EV-to-EBIT Range
Min: -208.4   Max: 130
Current: 7.41

-208.4
130
Shiller P/E 43.40
DEPO's Shiller P/E is ranked lower than
58% of the 412 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.08 vs. DEPO: 43.40 )
Ranked among companies with meaningful Shiller P/E only.
DEPO' s 10-Year Shiller P/E Range
Min: 21.62   Max: 123.75
Current: 43.4

21.62
123.75
Current Ratio 9.94
DEPO's Current Ratio is ranked higher than
89% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. DEPO: 9.94 )
Ranked among companies with meaningful Current Ratio only.
DEPO' s 10-Year Current Ratio Range
Min: 0.57   Max: 56
Current: 9.94

0.57
56
Quick Ratio 9.84
DEPO's Quick Ratio is ranked higher than
91% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. DEPO: 9.84 )
Ranked among companies with meaningful Quick Ratio only.
DEPO' s 10-Year Quick Ratio Range
Min: 0.57   Max: 56
Current: 9.84

0.57
56
Days Inventory 192.98
DEPO's Days Inventory is ranked lower than
81% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.86 vs. DEPO: 192.98 )
Ranked among companies with meaningful Days Inventory only.
DEPO' s 10-Year Days Inventory Range
Min: 93.22   Max: 613.73
Current: 192.98

93.22
613.73
Days Sales Outstanding 24.74
DEPO's Days Sales Outstanding is ranked higher than
87% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.43 vs. DEPO: 24.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
DEPO' s 10-Year Days Sales Outstanding Range
Min: 12.13   Max: 54004.13
Current: 24.74

12.13
54004.13

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.40
DEPO's Price/Tangible Book is ranked higher than
57% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.50 vs. DEPO: 4.40 )
Ranked among companies with meaningful Price/Tangible Book only.
DEPO' s 10-Year Price/Tangible Book Range
Min: 2.54   Max: 87
Current: 4.4

2.54
87
Price/DCF (Projected) 7.40
DEPO's Price/DCF (Projected) is ranked lower than
74% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. DEPO: 7.40 )
Ranked among companies with meaningful Price/DCF (Projected) only.
DEPO' s 10-Year Price/DCF (Projected) Range
Min: 1.18   Max: 335
Current: 7.4

1.18
335
Price/Median PS Value 1.10
DEPO's Price/Median PS Value is ranked higher than
85% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. DEPO: 1.10 )
Ranked among companies with meaningful Price/Median PS Value only.
DEPO' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 123.5
Current: 1.1

0.39
123.5
Price/Graham Number 1.60
DEPO's Price/Graham Number is ranked higher than
84% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. DEPO: 1.60 )
Ranked among companies with meaningful Price/Graham Number only.
DEPO' s 10-Year Price/Graham Number Range
Min: 0.61   Max: 7.48
Current: 1.6

0.61
7.48
Earnings Yield (Greenblatt) 12.70
DEPO's Earnings Yield (Greenblatt) is ranked higher than
95% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.00 vs. DEPO: 12.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
DEPO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 251.9
Current: 12.7

0.8
251.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DPO.Germany,
DepoMed Inc was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. The Products that comprise its specialty pharmaceutical business are Gralise, Zipsor (diclofenac potassium) liquid filled capsules, its non-steriodal anti-inflammatory drug for the treatment of mild to moderate acute pain, CAMBIA, its non-steriodal anti-inflammatory drug for the acute treatment of migraine attacks, and Lazanda nasal spray, its product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The Company's operation and business are subject to a number of other laws and regulations, including those relating to the workplace, privacy, laboratory practices and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances as well as controlled substances.
» More Articles for DEPO

Headlines

Articles On GuruFocus.com
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Reports Second Quarter 2009 Financial Results Jul 30 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
O'Malley jabs Wall Street, presidential dynasties Jun 01 2015
Who's The Next Big Pharma Acquisition? May 29 2015
Depomed To Present At Healthcare Conferences In June May 26 2015
Depomed To Present At Healthcare Conferences In June May 26 2015
DEPOMED INC Financials May 22 2015
DEPOMED INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... May 19 2015
Best 100 Hedge Funds May 15 2015
10-Q for Depomed, Inc. May 13 2015
Depomed To Present At Healthcare Conferences In May May 13 2015
DEPOMED INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 13 2015
Depomed To Present At Healthcare Conferences In May May 13 2015
Biotech provides a major plus for the stock market May 13 2015
DEPO: Selloff Creates Great Opportunity In Depomed May 13 2015
Why the DepoMed Drop Is a Gross Overreaction May 12 2015
Depomed (DEPO) Stock Falls on Earnings Miss May 12 2015
5 Drug Stocks Moving On Earnings, Trial Data Late May 11 2015
Virtusa, Ocean Rig, magicJack Lead Monday's After-Hours Movers May 11 2015
After-hours buzz: Rackspace, Gap, Depomed & more May 11 2015
Depomed reports 1Q loss May 11 2015
Depomed reports 1Q loss May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK